lymphocytic lymphoma


Also found in: Encyclopedia.

lymphocytic lymphoma, lymphocytic lymphosarcoma

lymphocytic lymphoma

Non-Hodgkin's lymphoma, see there.
References in periodicals archive ?
Proliferation centers are useful for the recognition of B-cell small lymphocytic lymphoma, and a nodular growth pattern may have clinical relevance for follicle center and mantle cell neoplasms.
Specific NHL diagnoses included are: small lymphocytic lymphoma or follicular lymphoma (small cleaved, mixed or large cell) as classified by the International Working Formulation Classification; or small lymphocytic, lymphoplasmacytoid, marginal, or follicular lymphoma as categorized by the Revised European-American Lymphoma (REAL) classification of the International Lymphoma Study Group (ILSG).
is indicated for the treatment of relapsed follicular B-Cell non-Hodgkin lymphoma (FL), small lymphocytic lymphoma, and in combination with rituximab for patients with relapsed chronic lymphocytic leukemia (CLL).
Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) is a significant advance for patients with these blood cancers.
For certain patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, alemtuzumab (Campath[R], Genzyme) was added as a first-line therapy option.
Functional Evidence Using Deuterated Water Labeling that the Bruton Tyrosine Kinase Inhibitor Ibrutinib Inhibits Leukemia Cell Proliferation/Trafficking and Promotes Leukemia Cell Death in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (Abstract 326) CLL: Therapy, excluding Transplantation: Novel Therapies.
During the course of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), a transition to an aggressive large cell lymphoma may occur.
Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): first results from a randomized, double-blind, placebo-controlled, phase III study.
Zydelig is suggested for the treatment of regressed follicular B-Cell non-Hodgkin lymphoma (FL), small lymphocytic lymphoma, and in combination with rituximab for patients with relapsed chronic lymphocytic leukaemia (CLL).
Based on the morphologic features alone, differential diagnostic considerations in this case includes small B-cell non-Hodgkin lymphomas including chronic lymphocytic leukemia/small lymphocytic lymphoma, marginal zone lymphoma, and mantle cell lymphoma.
CLL is regarded as small lymphocytic lymphoma when lymph nodes are involved but the blood film and, in particular, the white blood cell count is normal.
Abstract: A 65-year-old male with peripheral neuropathy and small lymphocytic lymphoma presented with erythema and edema of the left foot.

Full browser ?